Posted by Michael Wonder on 11 Jul 2019
Proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation therapeutic areas
11 July 2019 - PHARMAC is seeking feedback on proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation therapeutic areas.
In summary, the proposals would result in the following changes from 1 September 2019:
- Adalimumab (Humira) access would be widened to include treatment of severe or chronic ocular inflammation.
- Dexrazoxane would be funded in DHB hospitals for cardioprotection in children and young adults treated with anthracycline chemotherapy.
- Sildenafil access would be widened to include people who have erectile dysfunction as a result of spinal cord injury.
Read PHARMAC Consultation